Last updated on March 2017

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens


Brief description of study

The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related Adverse Events (TDRAE) over the period following enrollment.

Clinical Study Identifier: NCT02625155

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Donald H. Deaton, DO

Donald H. Deaton, Jr., DO
Tazewell, TN United States
  Connect »